Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 609-617
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Deciphering breast cancer: from biology to the clinic
Emma Nolan, Geoffrey J. Lindeman, Jane E. Visvader
Cell (2023) Vol. 186, Iss. 8, pp. 1708-1728
Open Access | Times Cited: 354
Rare molecular subtypes of lung cancer
Guilherme Harada, Soo‐Ryum Yang, Emiliano Cocco, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 229-249
Open Access | Times Cited: 75
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 2012-2031
Open Access | Times Cited: 69
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
The intrinsic substrate specificity of the human tyrosine kinome
Tomer M. Yaron, Brian A. Joughin, Emily M. Huntsman, et al.
Nature (2024) Vol. 629, Iss. 8014, pp. 1174-1181
Open Access | Times Cited: 40
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 21
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 21
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
Francesco Facchinetti, Antoine Hollebecque, Floriane Brayé, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 1998-2011
Open Access | Times Cited: 39
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Qibiao Wu, Haley Ellis, Giulia Siravegna, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 198-208
Open Access | Times Cited: 39
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 36
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Pashtoon Murtaza Kasi, Jessica Lee, Lincoln W. Pasquina, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 836-848
Open Access | Times Cited: 25
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
Jinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112538-112538
Open Access | Times Cited: 24
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies
Francesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 21, pp. 4943-4956
Open Access | Times Cited: 11
Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2
Feng Liu, Ling Tang, H.J. Liu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 10
Finding a needle in a haystack: functional screening for novel targets in cancer immunology and immunotherapies
Yi Du, Yang Yang, Bohao Zheng, et al.
Oncogene (2025)
Open Access | Times Cited: 1
The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer
Jiacheng He, Xiaolei Chai, Qiansen Zhang, et al.
Nature Immunology (2025)
Closed Access | Times Cited: 1
Current progress in cancer treatment by targeting FGFR signaling
Sicheng Du, Ying Zhang, Jianming Xu
Cancer Biology and Medicine (2023) Vol. 20, Iss. 7, pp. 490-499
Open Access | Times Cited: 21
Clinical value of liquid biopsy in FGFR2 fusion-positive cholangiocarcinoma patients during targeted therapy
Alberto González‐Medina, María Vila-Casadesús, Marina Gómez-Rey, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 19, pp. 4491-4504
Open Access | Times Cited: 7
Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression
Hong Tian, Jiali Yu, Xiaoli Chu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Genetic differences between smokers and never-smokers with lung cancer
Piotr Kuśnierczyk
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer
Lewis Au, J. Collin, John M. Mariadason
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1117-1117
Open Access | Times Cited: 5
Taraxasterol suppresses the proliferation and tumor growth of androgen-independent prostate cancer cells through the FGFR2-PI3K/AKT signaling pathway
Jinqiu Yang, Chulin Xin, Guangfen Yin, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma
Yuanli Zhen, Kai Liu, Lei Shi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2− Breast Cancer Preclinical Models
Satoshi Kawano, Sayo Fukushima, Kyoko Nishibata, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1084-1084
Open Access
Regulation of alternative splicing in Catharanthus roseus in response to methyl jasmonate modulation during development and stress resilience
Aala A. Abulfaraj, Abeer Al‐Andal
Functional Plant Biology (2025) Vol. 52, Iss. 4
Closed Access
Page 1 - Next Page

Scroll to top